Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EP MedSystems

This article was originally published in The Gray Sheet

Executive Summary

Cardiac electrophysiology products company's $3.25 mil. equity financing agreement is led by Cardiac Capital, which is 50% owned by EP MedSystems Chairman and CEO David Jenkins. Cardiac Capital will receive 1.5 mil. shares of common stock and warrants for 750,000 additional shares exercisable at $4, out of a total 1.63 mil. shares and 812,500 warrants. Jenkins has agreed not to sell any previously owned shares for one year after the deal closes. Proceeds will be used to expand the Mt. Arlington, New Jersey firm's sales, marketing and manufacturing capabilities. FDA has granted EP MedSystems' ALERT catheter expedited PMA review for treatment of atrial fibrillation

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel